Nxera Pharma Advances Schizophrenia Treatment
Company Announcements

Nxera Pharma Advances Schizophrenia Treatment

Sosei Group (JP:4565) has released an update.

Nxera Pharma reports positive Phase 2 results for NBI-1117568, a potential new once-daily oral treatment for schizophrenia showing significant symptom improvement. Developed in partnership with Neurocrine Biosciences, the drug met primary and secondary endpoints with good safety and tolerability. This success paves the way for Phase 3 trials and highlights the strength of Nxera’s NxWave discovery platform in addressing complex neurological disorders.

For further insights into JP:4565 stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Japan Auto-Generated NewsdeskNxera Pharma Gains Milestone Payment in Sleep Disorder Collaboration
TipRanks Auto-Generated NewsdeskNxera Pharma Reports Robust Revenue Growth Amid Strategic Expansion
TipRanks Japan Auto-Generated NewsdeskNxera Pharma Reports Increased Revenue but Continues to Face Losses
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App